Compare CART & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CART | ARWR |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.0B |
| IPO Year | 2023 | 2009 |
| Metric | CART | ARWR |
|---|---|---|
| Price | $38.89 | $60.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | $52.24 | ★ $81.50 |
| AVG Volume (30 Days) | ★ 3.6M | 2.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.27 | ★ 99.80 |
| EPS | ★ 1.60 | 0.22 |
| Revenue | ★ $3,742,000,000.00 | $16,142,321.00 |
| Revenue This Year | $13.36 | N/A |
| Revenue Next Year | $9.57 | N/A |
| P/E Ratio | ★ $24.22 | $277.32 |
| Revenue Growth | ★ 10.78 | N/A |
| 52 Week Low | $32.73 | $10.92 |
| 52 Week High | $53.50 | $76.76 |
| Indicator | CART | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 52.23 |
| Support Level | $35.28 | $60.60 |
| Resistance Level | $40.03 | $66.37 |
| Average True Range (ATR) | 1.34 | 3.03 |
| MACD | 0.17 | 0.76 |
| Stochastic Oscillator | 84.57 | 61.58 |
Maplebear (Instacart) is a grocery-focused delivery marketplace that connects national and regional grocers with consumers and couriers, and consumers with their favorite stores. Its app provides on-demand convenience for consumers, allows couriers to earn income, and helps grocers to scale their business through digital channels. The marketplace gathers valuable consumer behavior data, attracting consumer-packaged-goods advertisers that seek to reach consumers at the point of purchase. With approximately 600,000 shoppers and 1,800 retail partners, Instacart delivers to about 98% of households in the United States and Canada.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.